| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antifungal Agents | 13 | 2019 | 1828 | 1.76 | Why? |
| Clostridium Infections | 9 | 2020 | 595 | 1.63 | Why? |
| Enterococcus faecium | 5 | 2019 | 95 | 1.34 | Why? |
| Fecal Microbiota Transplantation | 9 | 2021 | 372 | 1.23 | Why? |
| Gram-Negative Bacterial Infections | 3 | 2019 | 398 | 1.13 | Why? |
| Gram-Positive Bacterial Infections | 6 | 2019 | 323 | 1.11 | Why? |
| Biofilms | 5 | 2020 | 304 | 1.00 | Why? |
| Microbial Sensitivity Tests | 10 | 2019 | 2886 | 1.00 | Why? |
| Bacterial Proteins | 12 | 2019 | 1318 | 0.91 | Why? |
| Coated Materials, Biocompatible | 2 | 2020 | 113 | 0.90 | Why? |
| Anti-Bacterial Agents | 20 | 2021 | 10083 | 0.89 | Why? |
| Graphite | 3 | 2020 | 318 | 0.87 | Why? |
| Entomophthorales | 1 | 2019 | 2 | 0.82 | Why? |
| Zygomycosis | 1 | 2019 | 8 | 0.80 | Why? |
| Itraconazole | 2 | 2019 | 135 | 0.79 | Why? |
| Duodenal Ulcer | 1 | 2019 | 27 | 0.77 | Why? |
| Escherichia coli | 5 | 2019 | 1547 | 0.74 | Why? |
| Invasive Fungal Infections | 3 | 2019 | 274 | 0.74 | Why? |
| Drug Resistance, Fungal | 6 | 2019 | 191 | 0.74 | Why? |
| Klebsiella pneumoniae | 3 | 2018 | 658 | 0.68 | Why? |
| Gram-Positive Bacteria | 1 | 2019 | 230 | 0.68 | Why? |
| Gram-Negative Bacteria | 2 | 2019 | 473 | 0.67 | Why? |
| Acinetobacter baumannii | 3 | 2019 | 378 | 0.66 | Why? |
| Voriconazole | 3 | 2018 | 206 | 0.65 | Why? |
| Bacteremia | 5 | 2019 | 1372 | 0.65 | Why? |
| Triazoles | 3 | 2018 | 440 | 0.64 | Why? |
| Candidemia | 5 | 2018 | 353 | 0.63 | Why? |
| Staphylococcus aureus | 3 | 2021 | 844 | 0.60 | Why? |
| Aspergillus | 2 | 2017 | 347 | 0.57 | Why? |
| Equipment and Supplies | 1 | 2020 | 440 | 0.57 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 5 | 2018 | 449 | 0.56 | Why? |
| Diabetic Foot | 1 | 2019 | 317 | 0.56 | Why? |
| Pseudomonas aeruginosa | 3 | 2019 | 652 | 0.55 | Why? |
| Aspergillosis | 1 | 2017 | 264 | 0.51 | Why? |
| Bacteria | 3 | 2020 | 1897 | 0.47 | Why? |
| Donor Selection | 5 | 2021 | 804 | 0.45 | Why? |
| Diagnostic Imaging | 1 | 2019 | 1044 | 0.42 | Why? |
| Enterococcus faecalis | 3 | 2019 | 126 | 0.39 | Why? |
| Gastrointestinal Microbiome | 7 | 2020 | 1961 | 0.39 | Why? |
| Candida albicans | 4 | 2018 | 217 | 0.39 | Why? |
| Bacterial Toxins | 3 | 2019 | 185 | 0.37 | Why? |
| Fungal Proteins | 3 | 2018 | 133 | 0.37 | Why? |
| Candida parapsilosis | 2 | 2018 | 34 | 0.36 | Why? |
| Enterotoxins | 2 | 2019 | 115 | 0.36 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.34 | Why? |
| Drug Resistance, Bacterial | 6 | 2019 | 1414 | 0.34 | Why? |
| Diarrhea | 1 | 2019 | 2743 | 0.32 | Why? |
| Diabetes Complications | 1 | 2019 | 2358 | 0.32 | Why? |
| beta-Glucans | 2 | 2018 | 176 | 0.31 | Why? |
| Antigens, Bacterial | 2 | 2019 | 330 | 0.30 | Why? |
| Drug Resistance, Multiple, Bacterial | 4 | 2019 | 1115 | 0.28 | Why? |
| Candida glabrata | 2 | 2017 | 50 | 0.27 | Why? |
| Gene Expression Regulation, Bacterial | 3 | 2018 | 143 | 0.26 | Why? |
| Pneumonia, Ventilator-Associated | 2 | 2021 | 861 | 0.25 | Why? |
| Cross Infection | 5 | 2019 | 8675 | 0.24 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.23 | Why? |
| Mycobacterium tuberculosis | 4 | 2018 | 1164 | 0.23 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.23 | Why? |
| Hafnia alvei | 1 | 2021 | 16 | 0.23 | Why? |
| Mycoses | 2 | 2018 | 589 | 0.22 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.22 | Why? |
| Humans | 95 | 2021 | 930598 | 0.22 | Why? |
| Stenotrophomonas maltophilia | 2 | 2019 | 63 | 0.22 | Why? |
| Antibodies, Fungal | 2 | 2017 | 49 | 0.21 | Why? |
| Invasive Pulmonary Aspergillosis | 2 | 2019 | 634 | 0.21 | Why? |
| Nucleoside-Phosphate Kinase | 1 | 2020 | 55 | 0.21 | Why? |
| Microbiota | 3 | 2021 | 1240 | 0.21 | Why? |
| Osteopontin | 1 | 2021 | 96 | 0.21 | Why? |
| fas Receptor | 1 | 2020 | 85 | 0.21 | Why? |
| Repressor Proteins | 2 | 2019 | 232 | 0.21 | Why? |
| Catheter-Related Infections | 3 | 2019 | 381 | 0.21 | Why? |
| Psychrobacter | 1 | 2019 | 1 | 0.20 | Why? |
| Bacteria, Anaerobic | 1 | 2019 | 20 | 0.20 | Why? |
| Italy | 17 | 2021 | 38444 | 0.20 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.20 | Why? |
| Rhodotorula | 1 | 2018 | 4 | 0.20 | Why? |
| Enterocolitis, Pseudomembranous | 2 | 2018 | 93 | 0.20 | Why? |
| Blood Culture | 2 | 2019 | 308 | 0.20 | Why? |
| Peptic Ulcer Perforation | 1 | 2019 | 29 | 0.19 | Why? |
| Tight Junctions | 1 | 2020 | 179 | 0.19 | Why? |
| Lectins | 2 | 2021 | 311 | 0.19 | Why? |
| Mycobacterium smegmatis | 1 | 2018 | 27 | 0.19 | Why? |
| Gastroenterology | 2 | 2020 | 1352 | 0.19 | Why? |
| Brucella | 1 | 2018 | 14 | 0.19 | Why? |
| Larynx, Artificial | 1 | 2018 | 27 | 0.19 | Why? |
| Fish Proteins | 1 | 2019 | 54 | 0.19 | Why? |
| Phagocytosis | 2 | 2019 | 409 | 0.19 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.18 | Why? |
| Biochemical Phenomena | 1 | 2017 | 8 | 0.18 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.18 | Why? |
| Metronidazole | 1 | 2018 | 59 | 0.18 | Why? |
| Nanocomposites | 1 | 2018 | 62 | 0.18 | Why? |
| Streptococcus | 1 | 2018 | 76 | 0.18 | Why? |
| Bacterial Vaccines | 1 | 2019 | 139 | 0.18 | Why? |
| Cefotaxime | 1 | 2017 | 31 | 0.18 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2018 | 45 | 0.18 | Why? |
| LIM-Homeodomain Proteins | 1 | 2017 | 7 | 0.18 | Why? |
| Communicable Diseases | 3 | 2018 | 2148 | 0.18 | Why? |
| RNA, Small Untranslated | 1 | 2017 | 11 | 0.18 | Why? |
| Sterol 14-Demethylase | 1 | 2017 | 8 | 0.18 | Why? |
| Vancomycin | 2 | 2018 | 328 | 0.18 | Why? |
| Phosphates | 1 | 2018 | 135 | 0.18 | Why? |
| Glucans | 1 | 2017 | 13 | 0.18 | Why? |
| Diverticular Diseases | 1 | 2017 | 26 | 0.18 | Why? |
| Phosphatidylinositol Phosphates | 1 | 2017 | 8 | 0.18 | Why? |
| Antigens, Fungal | 1 | 2018 | 106 | 0.18 | Why? |
| Staphylococcus | 1 | 2018 | 77 | 0.17 | Why? |
| Transcription Factors | 2 | 2017 | 784 | 0.17 | Why? |
| Genes, Fungal | 1 | 2017 | 21 | 0.17 | Why? |
| Adhesins, Bacterial | 1 | 2017 | 39 | 0.17 | Why? |
| Viral Envelope Proteins | 2 | 2020 | 3539 | 0.17 | Why? |
| Candidiasis | 3 | 2018 | 334 | 0.17 | Why? |
| Ureaplasma urealyticum | 1 | 2017 | 10 | 0.17 | Why? |
| Tuberculosis | 3 | 2018 | 2895 | 0.17 | Why? |
| Mycoplasma hominis | 1 | 2017 | 15 | 0.17 | Why? |
| Ureaplasma Infections | 1 | 2017 | 12 | 0.17 | Why? |
| Muscle Proteins | 1 | 2017 | 64 | 0.17 | Why? |
| Haemophilus influenzae | 1 | 2018 | 196 | 0.17 | Why? |
| Liver Diseases, Alcoholic | 1 | 2018 | 101 | 0.17 | Why? |
| Agar | 1 | 2016 | 15 | 0.17 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2019 | 159 | 0.17 | Why? |
| Medical Laboratory Science | 1 | 2018 | 122 | 0.17 | Why? |
| Osteomyelitis | 1 | 2019 | 131 | 0.17 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.17 | Why? |
| Reproductive Tract Infections | 1 | 2017 | 45 | 0.17 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.17 | Why? |
| Endotoxemia | 1 | 2018 | 143 | 0.16 | Why? |
| Mycoplasma Infections | 1 | 2017 | 65 | 0.16 | Why? |
| Antigens, Surface | 1 | 2017 | 181 | 0.16 | Why? |
| Liver Cirrhosis | 2 | 2018 | 1810 | 0.16 | Why? |
| Azoles | 1 | 2018 | 185 | 0.16 | Why? |
| Vancomycin-Resistant Enterococci | 1 | 2017 | 104 | 0.16 | Why? |
| Postnatal Care | 1 | 2020 | 346 | 0.16 | Why? |
| Microbiology | 1 | 2018 | 134 | 0.16 | Why? |
| Oxides | 1 | 2016 | 77 | 0.16 | Why? |
| Health | 1 | 2017 | 130 | 0.16 | Why? |
| Candidiasis, Invasive | 1 | 2017 | 107 | 0.16 | Why? |
| Biomimetic Materials | 1 | 2016 | 70 | 0.16 | Why? |
| Prospective Studies | 14 | 2021 | 43301 | 0.16 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.15 | Why? |
| Interferon-gamma Release Tests | 1 | 2018 | 253 | 0.15 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.15 | Why? |
| Skin Diseases, Bacterial | 1 | 2017 | 105 | 0.15 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2017 | 170 | 0.15 | Why? |
| Infant, Newborn, Diseases | 1 | 2020 | 394 | 0.15 | Why? |
| Patient Selection | 3 | 2020 | 4560 | 0.15 | Why? |
| Soft Tissue Infections | 1 | 2017 | 116 | 0.15 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.15 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.15 | Why? |
| Aspergillus fumigatus | 1 | 2018 | 239 | 0.15 | Why? |
| Staphylococcal Infections | 3 | 2021 | 1099 | 0.15 | Why? |
| Klebsiella Infections | 2 | 2018 | 466 | 0.15 | Why? |
| Reagent Kits, Diagnostic | 3 | 2021 | 2149 | 0.14 | Why? |
| Hydrogels | 1 | 2016 | 173 | 0.14 | Why? |
| Enterobacteriaceae Infections | 1 | 2021 | 529 | 0.14 | Why? |
| Expert Testimony | 1 | 2019 | 658 | 0.14 | Why? |
| Societies, Scientific | 1 | 2018 | 414 | 0.14 | Why? |
| Irritable Bowel Syndrome | 1 | 2017 | 175 | 0.14 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.14 | Why? |
| Liposomes | 1 | 2017 | 334 | 0.14 | Why? |
| Conjunctiva | 1 | 2020 | 620 | 0.14 | Why? |
| Gastrointestinal Agents | 1 | 2019 | 393 | 0.14 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.14 | Why? |
| Colonoscopy | 2 | 2018 | 738 | 0.14 | Why? |
| Pericardium | 1 | 2017 | 228 | 0.14 | Why? |
| Escherichia coli Infections | 1 | 2018 | 348 | 0.14 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.14 | Why? |
| Arabs | 1 | 2017 | 298 | 0.14 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.14 | Why? |
| Latent Tuberculosis | 1 | 2018 | 324 | 0.13 | Why? |
| Microbial Viability | 4 | 2019 | 406 | 0.13 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.13 | Why? |
| Catheterization, Central Venous | 1 | 2019 | 458 | 0.13 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.13 | Why? |
| Th17 Cells | 1 | 2019 | 657 | 0.13 | Why? |
| International Cooperation | 2 | 2017 | 3436 | 0.13 | Why? |
| Animals | 19 | 2021 | 78931 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Lymphocyte Subsets | 1 | 2020 | 987 | 0.13 | Why? |
| Biological Specimen Banks | 1 | 2021 | 1142 | 0.13 | Why? |
| Curcumin | 1 | 2018 | 396 | 0.12 | Why? |
| Intensive Care Units | 9 | 2021 | 29594 | 0.12 | Why? |
| Specialization | 1 | 2017 | 432 | 0.12 | Why? |
| Cytomegalovirus Infections | 1 | 2019 | 667 | 0.12 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.12 | Why? |
| Middle East | 1 | 2017 | 1418 | 0.12 | Why? |
| Recurrence | 5 | 2021 | 3675 | 0.12 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.11 | Why? |
| Milk, Human | 1 | 2020 | 956 | 0.11 | Why? |
| Health Services | 1 | 2017 | 765 | 0.11 | Why? |
| Feces | 6 | 2021 | 4235 | 0.11 | Why? |
| Male | 35 | 2021 | 367725 | 0.11 | Why? |
| Host-Pathogen Interactions | 4 | 2020 | 11041 | 0.11 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.11 | Why? |
| Blood Transfusion | 1 | 2020 | 1399 | 0.11 | Why? |
| Amino Acid Sequence | 5 | 2020 | 6049 | 0.11 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.11 | Why? |
| Epitopes | 2 | 2020 | 4113 | 0.11 | Why? |
| Fluconazole | 3 | 2018 | 145 | 0.10 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.10 | Why? |
| Coronary Artery Bypass | 1 | 2017 | 629 | 0.10 | Why? |
| Health Planning | 1 | 2017 | 607 | 0.10 | Why? |
| Computational Biology | 3 | 2020 | 4514 | 0.10 | Why? |
| Safety | 1 | 2018 | 1583 | 0.10 | Why? |
| Inflammasomes | 1 | 2017 | 710 | 0.10 | Why? |
| Membrane Proteins | 1 | 2020 | 1733 | 0.10 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.10 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.10 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.10 | Why? |
| Sensitivity and Specificity | 6 | 2021 | 22971 | 0.10 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.10 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.10 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.10 | Why? |
| Point-of-Care Testing | 2 | 2021 | 2782 | 0.10 | Why? |
| Colitis, Ulcerative | 1 | 2019 | 1037 | 0.10 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Female | 34 | 2021 | 380317 | 0.09 | Why? |
| Antigens, Viral | 3 | 2021 | 6298 | 0.09 | Why? |
| ATP-Binding Cassette Transporters | 1 | 2009 | 48 | 0.09 | Why? |
| Rome | 2 | 2021 | 497 | 0.09 | Why? |
| Tandem Repeat Sequences | 2 | 2018 | 78 | 0.09 | Why? |
| Bacterial Adhesion | 2 | 2018 | 69 | 0.09 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.09 | Why? |
| Scedosporium | 1 | 2008 | 9 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Mycetoma | 1 | 2008 | 12 | 0.09 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.09 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.09 | Why? |
| Quality Improvement | 2 | 2019 | 2435 | 0.09 | Why? |
| Aged | 23 | 2021 | 215776 | 0.09 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Polymerase Chain Reaction | 2 | 2020 | 6740 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Arthritis, Rheumatoid | 1 | 2021 | 2043 | 0.09 | Why? |
| Colony Count, Microbial | 2 | 2018 | 177 | 0.08 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.08 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.08 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.08 | Why? |
| Mutation | 5 | 2019 | 12376 | 0.08 | Why? |
| Europe | 6 | 2019 | 12702 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.08 | Why? |
| Macrophages | 4 | 2021 | 2784 | 0.08 | Why? |
| Hospitals, Teaching | 3 | 2020 | 1609 | 0.08 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2021 | 13720 | 0.08 | Why? |
| Specimen Handling | 3 | 2020 | 6190 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.08 | Why? |
| RNA, Viral | 4 | 2021 | 32276 | 0.08 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2020 | 5164 | 0.08 | Why? |
| Biomarkers | 6 | 2019 | 23361 | 0.08 | Why? |
| Disease Management | 3 | 2018 | 6841 | 0.08 | Why? |
| Patient Care | 1 | 2017 | 1664 | 0.08 | Why? |
| Rabbits | 2 | 2019 | 1171 | 0.07 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.07 | Why? |
| Parents | 1 | 2019 | 2758 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.07 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.07 | Why? |
| Acinetobacter Infections | 1 | 2008 | 273 | 0.07 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.07 | Why? |
| One Health | 2 | 2020 | 390 | 0.07 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.07 | Why? |
| Drug Discovery | 1 | 2019 | 3092 | 0.07 | Why? |
| Species Specificity | 2 | 2020 | 1356 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Lung | 4 | 2021 | 31049 | 0.07 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.07 | Why? |
| Protein Conformation | 3 | 2020 | 4386 | 0.07 | Why? |
| Gene Expression Regulation, Viral | 2 | 2020 | 925 | 0.07 | Why? |
| Trophoblasts | 1 | 2006 | 237 | 0.07 | Why? |
| Virulence | 3 | 2018 | 2172 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Aged, 80 and over | 12 | 2020 | 88759 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Adult | 18 | 2021 | 244371 | 0.07 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.07 | Why? |
| Pregnancy Complications, Infectious | 2 | 2020 | 11559 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Genome, Bacterial | 2 | 2017 | 446 | 0.07 | Why? |
| Sequence Alignment | 2 | 2020 | 2109 | 0.06 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.06 | Why? |
| Colon | 2 | 2019 | 669 | 0.06 | Why? |
| DNA, Bacterial | 2 | 2018 | 835 | 0.06 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Acute Coronary Syndrome | 1 | 2017 | 2107 | 0.06 | Why? |
| Candida | 2 | 2018 | 425 | 0.06 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.06 | Why? |
| Leukemia | 1 | 2008 | 598 | 0.06 | Why? |
| Intestines | 2 | 2018 | 817 | 0.06 | Why? |
| CD48 Antigen | 1 | 2021 | 27 | 0.06 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 2309 | 0.06 | Why? |
| S100A12 Protein | 1 | 2021 | 43 | 0.06 | Why? |
| Synovial Membrane | 1 | 2021 | 72 | 0.06 | Why? |
| Protein Domains | 3 | 2020 | 6563 | 0.06 | Why? |
| Serine Endopeptidases | 1 | 2017 | 4606 | 0.06 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2021 | 93 | 0.06 | Why? |
| Models, Molecular | 3 | 2020 | 7616 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Blood Bactericidal Activity | 1 | 2019 | 19 | 0.05 | Why? |
| Opsonin Proteins | 1 | 2019 | 18 | 0.05 | Why? |
| Mice | 5 | 2019 | 21357 | 0.05 | Why? |
| Phylogeny | 4 | 2020 | 13341 | 0.05 | Why? |
| Polysaccharides, Bacterial | 1 | 2019 | 59 | 0.05 | Why? |
| Dextran Sulfate | 1 | 2019 | 54 | 0.05 | Why? |
| Inflammatory Bowel Diseases | 1 | 2017 | 3209 | 0.05 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 243 | 0.05 | Why? |
| Microorganisms, Genetically-Modified | 1 | 2018 | 19 | 0.05 | Why? |
| Sequence Analysis, Protein | 1 | 2020 | 309 | 0.05 | Why? |
| Fatty Liver, Alcoholic | 1 | 2018 | 13 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| Analytic Sample Preparation Methods | 1 | 2018 | 5 | 0.05 | Why? |
| Cell Wall | 1 | 2019 | 62 | 0.05 | Why? |
| Renal Dialysis | 1 | 2016 | 4358 | 0.05 | Why? |
| Polytetrafluoroethylene | 1 | 2018 | 19 | 0.05 | Why? |
| Sonication | 1 | 2018 | 18 | 0.05 | Why? |
| Molecular Targeted Therapy | 2 | 2018 | 1579 | 0.05 | Why? |
| Silicones | 1 | 2018 | 26 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2019 | 3608 | 0.05 | Why? |
| Consensus | 3 | 2019 | 6345 | 0.05 | Why? |
| Immunity, Heterologous | 1 | 2019 | 129 | 0.05 | Why? |
| Toxicity Tests | 1 | 2019 | 100 | 0.05 | Why? |
| Amniotic Fluid | 1 | 2020 | 249 | 0.05 | Why? |
| Child | 8 | 2021 | 70012 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Organization and Administration | 1 | 2018 | 93 | 0.05 | Why? |
| Lipopolysaccharide Receptors | 1 | 2021 | 357 | 0.05 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.05 | Why? |
| Drug Liberation | 1 | 2018 | 141 | 0.05 | Why? |
| Lepidoptera | 1 | 2017 | 26 | 0.05 | Why? |
| Polysaccharide-Lyases | 1 | 2017 | 4 | 0.05 | Why? |
| Enzyme Stability | 1 | 2017 | 72 | 0.04 | Why? |
| Transaminases | 1 | 2018 | 152 | 0.04 | Why? |
| Interleukin-6 | 1 | 2016 | 7522 | 0.04 | Why? |
| Glucosyltransferases | 1 | 2017 | 29 | 0.04 | Why? |
| Haplorhini | 1 | 2018 | 307 | 0.04 | Why? |
| Tuberculin Test | 1 | 2018 | 141 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2019 | 5542 | 0.04 | Why? |
| Animal Shells | 1 | 2016 | 4 | 0.04 | Why? |
| Brachyura | 1 | 2016 | 5 | 0.04 | Why? |
| Critical Illness | 2 | 2019 | 17281 | 0.04 | Why? |
| Phagosomes | 1 | 2017 | 32 | 0.04 | Why? |
| Cytoplasm | 1 | 2019 | 304 | 0.04 | Why? |
| Cohort Studies | 5 | 2020 | 36005 | 0.04 | Why? |
| RNA, Bacterial | 1 | 2017 | 116 | 0.04 | Why? |
| B7-H1 Antigen | 1 | 2021 | 541 | 0.04 | Why? |
| Microscopy, Electron, Scanning | 1 | 2018 | 221 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Internship and Residency | 1 | 2018 | 4987 | 0.04 | Why? |
| Bronchoalveolar Lavage | 1 | 2021 | 603 | 0.04 | Why? |
| Deoxyribonuclease I | 1 | 2017 | 66 | 0.04 | Why? |
| Vaccines, Conjugate | 1 | 2019 | 328 | 0.04 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 286 | 0.04 | Why? |
| Surface Properties | 1 | 2018 | 448 | 0.04 | Why? |
| Sequence Homology, Amino Acid | 1 | 2020 | 945 | 0.04 | Why? |
| Amino Acid Substitution | 2 | 2018 | 1706 | 0.04 | Why? |
| Clinical Medicine | 1 | 2018 | 93 | 0.04 | Why? |
| Receptors, Immunologic | 1 | 2021 | 555 | 0.04 | Why? |
| Molecular Chaperones | 1 | 2017 | 124 | 0.04 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 11367 | 0.04 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2006 | 1731 | 0.04 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.04 | Why? |
| Microscopy, Electron, Transmission | 1 | 2019 | 605 | 0.04 | Why? |
| Prosthesis Failure | 1 | 2018 | 195 | 0.04 | Why? |
| Proteoglycans | 1 | 2017 | 130 | 0.04 | Why? |
| Endotoxins | 1 | 2016 | 80 | 0.04 | Why? |
| Biocompatible Materials | 1 | 2018 | 214 | 0.04 | Why? |
| Fetal Blood | 1 | 2020 | 573 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Emergency Service, Hospital | 2 | 2019 | 14232 | 0.04 | Why? |
| Lasers | 1 | 2016 | 132 | 0.04 | Why? |
| Antibody-Dependent Enhancement | 1 | 2020 | 413 | 0.04 | Why? |
| Laryngectomy | 1 | 2018 | 145 | 0.04 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 167 | 0.04 | Why? |
| Risk Adjustment | 1 | 2020 | 730 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Cervix Uteri | 1 | 2017 | 146 | 0.04 | Why? |
| Substrate Specificity | 1 | 2017 | 639 | 0.04 | Why? |
| Antibodies, Bacterial | 1 | 2019 | 510 | 0.04 | Why? |
| Collagen | 1 | 2017 | 222 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.04 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.04 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.04 | Why? |
| Prosthesis Design | 1 | 2018 | 594 | 0.04 | Why? |
| Genetic Fitness | 1 | 2017 | 339 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Fungi | 1 | 2018 | 471 | 0.04 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.04 | Why? |
| Dysbiosis | 1 | 2021 | 685 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.04 | Why? |
| Principal Component Analysis | 1 | 2017 | 689 | 0.04 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.04 | Why? |
| Living Donors | 1 | 2020 | 652 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2021 | 1475 | 0.03 | Why? |
| Biological Assay | 1 | 2017 | 367 | 0.03 | Why? |
| Infliximab | 1 | 2019 | 502 | 0.03 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Gestational Age | 1 | 2020 | 1488 | 0.03 | Why? |
| Mice, Inbred BALB C | 2 | 2019 | 5814 | 0.03 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.03 | Why? |
| Statistics as Topic | 1 | 2017 | 370 | 0.03 | Why? |
| Databases, Genetic | 1 | 2020 | 1127 | 0.03 | Why? |
| Spleen | 1 | 2018 | 877 | 0.03 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.03 | Why? |
| Vagina | 1 | 2017 | 327 | 0.03 | Why? |
| Abortion, Spontaneous | 1 | 2020 | 776 | 0.03 | Why? |
| Retrospective Studies | 7 | 2020 | 105322 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2019 | 600 | 0.03 | Why? |
| Sequence Deletion | 1 | 2018 | 674 | 0.03 | Why? |
| Polyethylene Glycols | 1 | 2018 | 574 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2018 | 848 | 0.03 | Why? |
| Transcriptome | 2 | 2017 | 3466 | 0.03 | Why? |
| Nose | 1 | 2020 | 1093 | 0.03 | Why? |
| Evidence-Based Medicine | 2 | 2017 | 3228 | 0.03 | Why? |
| Proteolysis | 1 | 2017 | 751 | 0.03 | Why? |
| Pseudomonas Infections | 1 | 2018 | 425 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Particle Size | 1 | 2018 | 1052 | 0.03 | Why? |
| Cell Membrane | 1 | 2018 | 743 | 0.03 | Why? |
| Vaccines, Subunit | 1 | 2019 | 1088 | 0.03 | Why? |
| Dog Diseases | 1 | 2020 | 745 | 0.03 | Why? |
| Pregnancy | 3 | 2020 | 23879 | 0.03 | Why? |
| Informed Consent | 1 | 2020 | 890 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Drug Carriers | 1 | 2018 | 590 | 0.03 | Why? |
| Program Evaluation | 1 | 2021 | 1929 | 0.03 | Why? |
| Serum Albumin | 1 | 2016 | 571 | 0.03 | Why? |
| Dogs | 1 | 2020 | 2529 | 0.03 | Why? |
| A549 Cells | 1 | 2018 | 2066 | 0.03 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.03 | Why? |
| Membrane Glycoproteins | 1 | 2021 | 2273 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.03 | Why? |
| Infant | 3 | 2021 | 30274 | 0.03 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.03 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.03 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 581 | 0.03 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.03 | Why? |
| Viral Tropism | 1 | 2020 | 1329 | 0.03 | Why? |
| Cell Line | 2 | 2017 | 12040 | 0.03 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.03 | Why? |
| Protein Multimerization | 1 | 2017 | 1336 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2017 | 992 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2019 | 10998 | 0.03 | Why? |
| Intestinal Mucosa | 1 | 2019 | 1046 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Workflow | 1 | 2020 | 2373 | 0.03 | Why? |
| Protein Binding | 2 | 2017 | 11430 | 0.03 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Delivery, Obstetric | 1 | 2020 | 1292 | 0.03 | Why? |
| Geography | 1 | 2017 | 1801 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Aftercare | 1 | 2020 | 1637 | 0.03 | Why? |
| Hand Hygiene | 1 | 2021 | 1493 | 0.03 | Why? |
| Length of Stay | 2 | 2019 | 11042 | 0.03 | Why? |
| Environmental Exposure | 1 | 2021 | 1558 | 0.03 | Why? |
| Apoptosis | 1 | 2020 | 2335 | 0.03 | Why? |
| Protein Interaction Domains and Motifs | 1 | 2017 | 2134 | 0.02 | Why? |
| Gene Expression Regulation, Fungal | 1 | 2009 | 21 | 0.02 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.02 | Why? |
| Hospital Units | 1 | 2017 | 1017 | 0.02 | Why? |
| Placenta | 1 | 2020 | 1531 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Phonocardiography | 1 | 1968 | 9 | 0.02 | Why? |
| Valsalva Maneuver | 1 | 1968 | 17 | 0.02 | Why? |
| Methicillin Resistance | 1 | 2008 | 77 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| RNA, Messenger | 2 | 2017 | 5131 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Carrier State | 1 | 2020 | 2100 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Mitral Valve Stenosis | 1 | 1968 | 29 | 0.02 | Why? |
| Catheters, Indwelling | 1 | 2008 | 84 | 0.02 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.02 | Why? |
| Infection Control | 3 | 2021 | 23131 | 0.02 | Why? |
| Choriocarcinoma | 1 | 2006 | 8 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2020 | 4155 | 0.02 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 33 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Drug Design | 1 | 2019 | 2627 | 0.02 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.02 | Why? |
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2006 | 45 | 0.02 | Why? |
| Risk | 1 | 2019 | 5288 | 0.02 | Why? |
| Amphotericin B | 1 | 2008 | 256 | 0.02 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2006 | 85 | 0.02 | Why? |
| Tumor Cells, Cultured | 1 | 2006 | 254 | 0.02 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.02 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.02 | Why? |
| beta-Lactams | 1 | 2008 | 210 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2016 | 5440 | 0.02 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.02 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2006 | 211 | 0.02 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Anticoagulants | 1 | 2006 | 9563 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| Aging | 1 | 2020 | 3581 | 0.02 | Why? |
| Neoplasm Invasiveness | 1 | 2006 | 582 | 0.02 | Why? |
| Mitral Valve Insufficiency | 1 | 1968 | 302 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.02 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Patient Discharge | 1 | 2019 | 5696 | 0.02 | Why? |
| Cell Movement | 1 | 2006 | 695 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.01 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Social Isolation | 1 | 2021 | 5932 | 0.01 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2019 | 48226 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Pyrimidines | 1 | 2008 | 1557 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Aortic Valve Stenosis | 1 | 1968 | 741 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Heart Defects, Congenital | 1 | 1968 | 933 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2006 | 3776 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Gene Expression | 1 | 2006 | 3332 | 0.01 | Why? |
| Acute Disease | 1 | 2008 | 6029 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Postoperative Complications | 1 | 2008 | 5861 | 0.01 | Why? |
| Case-Control Studies | 1 | 2008 | 17671 | 0.01 | Why? |